Spotlight on Bevacizumab in Advanced Colorectal Cancer, Breast Cancer, and Non-Small Cell Lung Cancer1

BioDrugs ◽  
2006 ◽  
Vol 20 (3) ◽  
pp. 193-195 ◽  
Author(s):  
Katherine A Lyseng-Williamson ◽  
Dean M Robinson
Keyword(s):  
Breast Cancer ◽  
Colorectal Cancer ◽  
Advanced Colorectal Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Cancer Breast

scholarly journals A Review on the Carcinogenic Roles of DSCAM-AS1

2021 ◽  
Vol 9 ◽  
Author(s):  
Soudeh Ghafouri-Fard ◽  
Tayyebeh Khoshbakht ◽  
Mohammad Taheri ◽  
Kaveh Ebrahimzadeh
Keyword(s):  
Breast Cancer ◽  
Colorectal Cancer ◽  
Antisense Rna ◽  
Breast Tumor ◽  
Cancer Colorectal ◽  
Small Cell ◽  
Small Cell Lung ◽  
Breast Tumor Cells ◽  
Non Coding Rnas

Long non-coding RNAs (lncRNAs) are a group of transcripts with fundamental roles in the carcinogenesis. DSCAM Antisense RNA 1 (DSCAM−AS1) is an example of this group of transcripts which has been firstly identified in an attempt to find differentially expressed transcripts between breast tumor cells and benign breast samples. The pathogenic roles of DSCAM-AS1 have been vastly assessed in breast cancer, yet its roles are not restricted to this type of cancer. Independent studies in non-small cell lung cancer, colorectal cancer, osteosarcoma, hepatocellular carcinoma, melanoma and cervical cancer have validated participation of DSCAM-AS1 in the carcinogenic processes. miR-577, miR-122-5p, miR-204-5p, miR-136, miR−137, miR−382, miR−183, miR−99, miR-3173-5p, miR-874-3p, miR-874-3p, miR-150-5p, miR-2467-3p, miR-216b, miR-384, miR-186-5p, miR-338-3p, miR-877-5p and miR-101 are among miRNAs which interact with DSCAM-AS1. Moreover, this lncRNA has interactions with Wnt/β-catenin pathway. The current study aims at summarization of the results of studies which focused on the assessment of oncogenic role of DSCAM-AS1.

scholarly journals Synthesis of Novel 1,2,3-Triazole-Dihydropyrimidinone Hybrids Using Multicomponent 1,3-Dipolar Cycloaddition (Click)–Biginelli Reactions: Anticancer Activity

Synlett ◽  
2020 ◽  
Vol 31 (06) ◽  
pp. 615-621
Author(s):  
Elisabete P. Carreiro ◽  
Ana M. Sena ◽  
Adrián Puerta ◽  
José M. Padrón ◽  
Anthony J. Burke
Keyword(s):  
Breast Cancer ◽  
Lung Cancer ◽  
Heterocyclic Ring ◽  
Small Cell ◽  
Dipolar Cycloaddition ◽  
Cancer Cervix ◽  
Small Cell Lung ◽  
Methyl Group ◽  
Cancer Breast ◽  
Biginelli Reactions

In this work, 21 novel (1,4-disubstituted 1,2,3-triazole)-dihydropyrimidinone (1,2,3-trzl-DHPM) type hybrids were synthesized and characterized. These were divided into two types: hybrids A (5 in total) containing the dihydropyrimidinone heterocyclic ring decorated with a 1,4-disubstituted 1,2,3-triazole in the C-5 position [these compounds were accessed by a multicomponent copper(I)-catalyzed azide alkyne cycloaddition (CuAAC) (or click)–Biginelli reactions with satisfactory yields (39–57%)] and hybrids B (16 in total) containing two 1,2,3-triazole units in the C-5 and C-6 methyl position of the DHPM. Hybrids B were synthesized via functionalization of the C-6 methyl group of hybrids A, a multistep sequence of reactions was used that included bromination, azidation, and a CuAAC. Hybrids B were obtained in very good to excellent yields (up to 99%). Some hybrids A and B were evaluated for their antiproliferative activity against different cancer cell lines that included A549 and SW1573 (non-small-cell lung), HBL-100 and T-47D (breast), HeLa (cervix) and WiDr (colon). Three of these hybrids were potent cell proliferation inhibitors of non-small-cell lung cancer, cervix cancer, breast cancer, and colon cancer.

Temozolomide therapy for patients with non-small cell lung cancer, breast cancer, or melanoma brain metastases.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. e12539-e12539
Author(s):  
D. R. Naskhletashvili ◽  
V. A. Gorbunova ◽  
M. B. Bychkov ◽  
G. E. Chmutin ◽  
V. B. Karahan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lung Cancer ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Cancer Breast ◽  
Melanoma Brain Metastases

scholarly journals Systemic therapy of brain metastases: non–small cell lung cancer, breast cancer, and melanoma

2016 ◽  
Vol 19 (1) ◽  
pp. i1-i24 ◽  
Author(s):  
Marc C. Chamberlain ◽  
Christina S. Baik ◽  
Vijayakrishna K. Gadi ◽  
Shailender Bhatia ◽  
Laura Q.M. Chow
Keyword(s):  
Breast Cancer ◽  
Lung Cancer ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Systemic Therapy ◽  
Small Cell ◽  
Small Cell Lung ◽  
Cancer Breast

scholarly journals Phase II studies of Elsamitrucin in breast cancer, colorectal cancer, non-small cell lung cancer and ovarian cancer

1994 ◽  
Vol 5 (4) ◽  
pp. 375-376 ◽  
Author(s):  
J. Verweij ◽  
J. Wanders ◽  
A.L. Nielsen ◽  
N. Pavlidis ◽  
F. Calabresi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Colorectal Cancer ◽  
Lung Cancer ◽  
Ovarian Cancer ◽  
Small Cell Lung Cancer ◽  
Phase Ii ◽  
Cancer Colorectal ◽  
Small Cell ◽  
Small Cell Lung ◽  
Phase Ii Studies

scholarly journals A meta-analysis of Watson for Oncology in clinical application

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Zhou Jie ◽  
Zeng Zhiying ◽  
Li Li
Keyword(s):  
Breast Cancer ◽  
Colorectal Cancer ◽  
Lung Cancer ◽  
Cancer Patients ◽  
Meta Analysis ◽  
Small Cell ◽  
Breast Cancer Patients ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Colorectal Cancer Patients

AbstractUsing the method of meta-analysis to systematically evaluate the consistency of treatment schemes between Watson for Oncology (WFO) and Multidisciplinary Team (MDT), and to provide references for the practical application of artificial intelligence clinical decision-support system in cancer treatment. We systematically searched articles about the clinical applications of Watson for Oncology in the databases and conducted meta-analysis using RevMan 5.3 software. A total of 9 studies were identified, including 2463 patients. When the MDT is consistent with WFO at the ‘Recommended’ or the ‘For consideration’ level, the overall concordance rate is 81.52%. Among them, breast cancer was the highest and gastric cancer was the lowest. The concordance rate in stage I–III cancer is higher than that in stage IV, but the result of lung cancer is opposite (P < 0.05).Similar results were obtained when MDT was only consistent with WFO at the "recommended" level. Moreover, the consistency of estrogen and progesterone receptor negative breast cancer patients, colorectal cancer patients under 70 years old or ECOG 0, and small cell lung cancer patients is higher than that of estrogen and progesterone positive breast cancer patients, colorectal cancer patients over 70 years old or ECOG 1–2, and non-small cell lung cancer patients, with statistical significance (P < 0.05). Treatment recommendations made by WFO and MDT were highly concordant for cancer cases examined, but this system still needs further improvement. Owing to relatively small sample size of the included studies, more well-designed, and large sample size studies are still needed.

Sign in / Sign up

Export Citation Format

Share Document